Blueprint Medicines
Lilly’s Retevmo Outperforms Gavreto in Lung Cancer Study
SG Tylor
Source – Eli Lilly In the ongoing rivalry between Eli Lilly and Blueprint Medicines over their RET inhibitors, Eli Lilly ...
Roche withdraws Gavreto approval, citing study impracticality
SG Tylor
Roche’s cancer drug Gavreto was withdrawn for the treatment of advanced RET-mutant medullary thyroid cancer, following discussions with the FDA. ...
